Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ORIC Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding ORIC Pharmaceuticals, Inc.’s stock price such as:

• ORIC Pharmaceuticals, Inc.’s current stock price and volume
• Why ORIC Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ORIC from analysts
• ORIC’s stock price momentum as measured by its relative strength

About ORIC Pharmaceuticals, Inc. (ORIC)

Before we jump into ORIC Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Want to learn more about ORIC Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ORIC Pharmaceuticals, Inc..

ORIC Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, ORIC Pharmaceuticals, Inc.’s stock price was $11.070.

ORIC Pharmaceuticals, Inc. is down 4.9% from its previous closing price of $11.640.

During the last market session, ORIC Pharmaceuticals, Inc.’s stock traded between $10.980 and $11.740. Currently, there are approximately 105.47 million shares outstanding for ORIC Pharmaceuticals, Inc..

ORIC Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ORIC Pharmaceuticals, Inc. Stock Price History

ORIC Pharmaceuticals, Inc.’s (ORIC) price is currently up 2.22% so far this month.

During the month of July, ORIC Pharmaceuticals, Inc.’s stock price has reached a high of $12.570 and a low of $10.290.

Over the last year, ORIC Pharmaceuticals, Inc. has hit prices as high as $14.930 and as low as $7.230. Year to date, ORIC Pharmaceuticals, Inc.’s stock is up 35.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ORIC Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded ORIC Pharmaceuticals, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate ORIC Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ORIC Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ORIC Pharmaceuticals, Inc. (ORIC) by visiting AAII Stock Evaluator.

Relative Price Strength of ORIC Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, ORIC Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 1.55%, which translates to a Momentum Score of 59 and is considered to be Average.

Want to learn more about how ORIC Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ORIC Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, ORIC Pharmaceuticals, Inc.’s stock price is $11.070, which is down 4.9% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ORIC Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.